- Home
- VNRX vs BOLD Comparison
VNRX vs BOLD Comparison
Compare VNRX & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VNRX | BOLD |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 25.7M |
| IPO Year | 2012 | 2024 |
Fundamental Metrics
Financial Performance| Metric | VNRX | BOLD |
|---|---|---|
| Price | $0.19 | $1.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.50 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 15.2M | 51.8K |
| Earning Date | 05-14-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,233,511.00 | N/A |
| Revenue This Year | $68.22 | N/A |
| Revenue Next Year | $382.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 59.10 | N/A |
| 52 Week Low | $0.17 | $0.96 |
| 52 Week High | $0.94 | $1.78 |
Technical Indicators
Market Signals| Indicator | VNRX | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 38.84 |
| Support Level | $0.17 | $0.99 |
| Resistance Level | $0.27 | $1.20 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 13.65 | 13.33 |
Price Performance
Historical ComparisonAbout VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.